Protalex, Inc announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active rheumatoid arthritis.
French drugmaker Sanofi-Aventis SA plans to give Genzyme Corp.'s orphan drug business, which focuses on rare diseases, some autonomy once it completes its $20.1 billion acquisition of the specialty drugmaker.
Health care giant Johnson & Johnson has recalled several lots of surgical sutures in the United Kingdom because of a risk they are unsterile. The recall began in late-December but U.K. regulators recently posted a notice about the action online.
Trius Therapeutics, Inc. announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections.
GeoVax is developing two vaccine components, both able to produce non-infectious virus-like particles in the body of a vaccine recipient. These non-infectious particles are designed to "train" the immune system of the vaccinated person to recognize HIV.
InterMune, Inc. announced that the European Commission has granted marketing authorization for Esbriet. Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis.
Infinity Pharmaceuticals, Inc. announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company, and Alkermes, Inc. announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON, an investigational type 2 diabetes therapy, to daily Victoza.
The VS800 virtual slide system from Olympus allows researchers to scan and review microscope slides in just minutes. The self-contained, eyepiece-free system offers customized proprietary Olympus optics for the highest quality scans.
PBL InterferonSource has launched the VeriPlex Human Interferon Multiplex ELISA kit, which allows simultaneous quantifying of Human Type I, II, and III interferons as well as related pro-inflammatory cytokines from a single biological sample.
VaxInnate Corporation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.
ACT Biotech, Inc. has filed a special protocol assessment with the U.S. Food and Drug Administration related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.
Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.
Researchers have shown that medicine designed at nanoscale offers unprecedented opportunities for targeted treatment of serious diseases such as cancer. However, research also shows that the body's immune system plays a part in the drug delivery process.
Merck KGaA has received a complete response letter from the U.S. Food and Drug Administration on the new drug application for Cladribine Tablets, its investigational oral formulation of cladribine, a therapy for relapsing-remitting multiple sclerosis.